Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 4/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | RXRG | P48443 | 3/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391219 | 0.89 | RXRA (0.80) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2387822 | 0.88 | RXRA (0.79) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL4907099 | 0.87 | RXRA (0.77) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2387464 | 0.87 | RXRA (0.76) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2388825 | 0.85 | RXRA (0.74) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2389536 | 0.84 | RXRA (0.72) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL4908309 | 0.83 | RXRA (0.71) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2388101 | 0.83 | RXRA (0.70) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL2390082 | 0.82 | RXRA (0.70) | RXRANR1H2NR1H3ALDH1A1KDM4E | |
| SCHEMBL5615072 | 0.82 | RXRA (0.69) | RXRANR1H2NR1H3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20150299136-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20160280661-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.